Mitsuhiko Hasebe
National Institute of Radiological Sciences
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mitsuhiko Hasebe.
International Journal of Oral Science | 2017
Nanami Yamamoto; Koji Kawaguchi; Hisako Fujihara; Mitsuhiko Hasebe; Yuta Kishi; Masaaki Yasukawa; Kenichi Kumagai; Yoshiki Hamada
The autofluorescence visualization method (AVM) uses blue excitation light to assist in the diagnosis of epithelial dysplasia. It detects epithelial dysplasia as a black area, which is known as fluorescence visualization loss (FVL). In this study, we evaluated the detection accuracy for epithelial dysplasia of the tongue using the objective AVM and assessed its possible clinical utility. Seventy-nine tongue specimens clinically suspected to have leukoplakia or squamous cell carcinoma (SCC) were analyzed. First, the AVM was subjectively performed using the Visually Enhanced Lesion scope (VELscope), and the iodine-staining method was then performed. After biopsy, the histopathological results and the luminance ratio between the lesion and healthy tissue were compared, and a receiver operating characteristic curve was created. The cutoff value for the objective AVM was determined; the lesion was considered FVL-positive or -negative when the luminance ratio was higher or lower than the cutoff value, respectively. The histopathological diagnoses among the 79 specimens were SCC (n=30), leukoplakia with dysplasia (n=34), and leukoplakia without dysplasia (n=15). The cutoff value of the luminance ratio was 1.62, resulting in 66 FVL-positive and 13 FVL-negative specimens. The luminance ratio was significantly higher in the epithelial dysplasia-positive than -negative group (P<0.000 1). The objective AVM showed much higher consistency between histopathological results than did the two methods (kappa statistic=0.656). In conclusion, objective autofluorescence visualization has a potential as an auxiliary method for diagnosis of epithelial dysplasia.
International Journal of Oral and Maxillofacial Surgery | 2017
Mitsuhiko Hasebe; Kyosan Yoshikawa; R. Nishii; K. Kawaguchi; T. Kamada; Yoshiki Hamada
The aim of this study was to determine whether l-methyl-[11C]-methionine (MET) positron emission tomography (PET) allows the prediction of outcomes in patients with head and neck mucosal malignant melanoma treated with carbon ion radiation therapy (CIRT). This was a retrospective cohort study involving 85 patients who underwent a MET-PET or MET-PET/computed tomography (CT) examination before and after CIRT. MET uptake in the tumour was evaluated semi-quantitatively using the tumour-to-normal tissue ratio (TNR). Local recurrence, metastasis, and outcome predictions were studied in terms of TNR before CIRT (TNRpre), TNR after CIRT (TNRpost), and the TNR change ratio. Kaplan-Meier curves revealed significant differences between patients with higher TNRpre values and those with lower TNRpre values in regard to local recurrence, metastasis, and outcome (log-rank test P<0.0001 for all three). There were also significant differences in metastasis rates and outcomes between patients with higher and lower TNRpost values (log-rank test P=0.0105 and P=0.027, respectively). The Cox proportional hazards model revealed TNRpre to be a factor significantly influencing the risk of local recurrence (hazard ratio (HR) 29.0, P<0.001), risk of metastasis (HR 2.67, P=0.024), and the outcome (HR 6.3, P<0.001). MET-PET or MET-PET/CT is useful for predicting the outcomes of patients with head and neck mucosal malignant melanoma treated with CIRT.
Molecular Imaging and Biology | 2008
Mitsuru Koizumi; Tsuneo Saga; Kyosan Yoshikawa; Kazutoshi Suzuki; Shigeru Yamada; Mitsuhiko Hasebe; Seiya Ohashi; Sherif Abd-Elrazek; Hiroyuki Ishikawa; Kenji Sagou; Katsumi Tamura; Ryusuke Hara; Hirotoshi Kato; Shigeo Yasuda; Takeshi Yanagi; Hirohiko Tsujii
Molecular Imaging and Biology | 2010
Mitsuhiko Hasebe; Kyosan Yoshikawa; Seiya Ohashi; Sachiko Toubaru; Koji Kawaguchi; Junichi Sato; Jun-etsu Mizoe; Hirohiko Tsujii
Anticancer Research | 2009
Katsumi Tamura; Kyosan Yoshikawa; Hiroyuki Ishikawa; Mitsuhiko Hasebe; Hiroshi Tsuji; T. Yanagi; Kazutoshi Suzuki; Atsushi Kubo; Hirohiko Tsujii
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Kyosan Yoshikawa; Mitsuhiko Hasebe; Seiya Ohashi; Sherif Abd-Elrazek; Hiroyuki Ishikawa; Katsumi Tamura; Katsuyuki Tanimoto; Susumu Kandatsu; Tsuneo Saga; Kazutoshi Suzuki
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Mitsuhiko Hasebe; Kyosan Yoshikawa; Sherif Abd-Elrazek; Seiya Ohashi; Katsumi Tamura; Tomoaki Tamaki; Shingo Kato; Susumu Kandatsu; Tsuneo Saga; Kanichi Seto
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Sherif Abd-Elrazek; Kyosan Yoshikawa; Mitsuhiko Hasebe; Seiya Ohashi; Hiroyuki Ishikawa; Kenji Sagou; Katsumi Tamura; Susumu Kandatsu; Masayuki Baba; Tsuneo Saga
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Sherif Abd-Elrazek; Kyosan Yoshikawa; Mitsuhiko Hasebe; Seiya Ohashi; Katsuyuki Tanimoto; Katsumi Tamura; Shingo Kato; Susumu Kandatsu; Kazutoshi Suzuki; Tsuneo Saga
Archive | 2008
Mitsuru Koizumi; Tsuneo Saga; Kyosan Yoshikawa; Kazutoshi Suzuki; Shigeru Yamada; Mitsuhiko Hasebe; Seiya Ohashi; Sherif Abd-Elrazek; Hiroyuki Ishikawa; Kenji Sagou; Katsumi Tamura; Ryusuke Hara; Hirotoshi Kato; Shigeo Yasuda; Takeshi Yanagi; Hirohiko Tsujii